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Abstract Promoter hypermethylation of tumor suppres-
sor genes seems to be an early event in breast carcino-
genesis and is potentially reversible. This makes
methylation a possible therapeutic target, a marker for
treatment response and/or a prognostic factor. Methylation
status of 40 tumor suppressor genes was compared between
53 primary breast tumors and their corresponding metas-
tases to brain, lung, liver, or skin. In paired analyses, a
significant decrease in methylation values was seen in
distant metastases compared to their primaries in 21/40
individual tumor suppressor genes. Furthermore, primary
tumors that metastasized to the liver clustered together, in
line with the finding that primary breast carcinomas that
metastasized to the brain, skin, or lung, showed higher
methylation values in up to 27.5 % of tumor suppressor
genes than primary carcinomas that metastasized to the
liver. Conversion in methylation status of several genes
from the primary tumor to the metastasis had prognostic
value, and methylation status of some genes in the
metastases predicted survival after onset of metastases.
Methylation levels for most of the analyzed tumor sup-
pressor genes were lower in distant metastases compared to
their primaries, pointing to the dynamic aspect of methy-
lation of these tumor suppressor genes during cancer pro-
gression. Also, specific distant metastatic sites seem to
show differences in methylation patterns, implying that
hypermethylation profiles of the primaries may steer site-
specific metastatic spread. Lastly, methylation status of the
metastases seems to have prognostic value. These
promising findings warrant further validation in larger pa-
tient cohorts and more tumor suppressor genes.
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MS-MLPA Methylation-specific multiplex ligand-
dependent probe amplification
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MAI Mitotic activity index
CpG Cytosine phosphate guanine
QM-MSP Quantitative multiplex methylation-specific
PCR
PCR Polymerase chain reaction
DTC Disseminated tumor cell
FFPE Formalin-fixed paraffin embedded
P Primary
M Metastasis
TSS Transcription start site
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Introduction
With 1.7 million new cases causing 522,000 deaths
worldwide per year, breast cancer is the leading cause of
female cancer death [1]. Early detection, optimal surgery,
and adjuvant therapy are the key strategies to improve
prognosis. Although 5-year overall survival increased from
77 % in the period 1978–1984 to 82 % in the period
1995–2003, about 16 % of patients will develop distant
metastases and eventually die of the disease [2]. Preferred
site of distant metastases strongly depends on the subtype
of breast cancer. Lobular-type breast cancer preferentially
metastasizes to bone, GI tract and ovaries, triple negative
breast cancer to liver and brain, and luminal breast cancer
to the bone and skin, while well-circulated organs like the
spleen and heart almost never harbor metastases [3–5].
This ‘‘organotropism’’ was first described by Paget et al.
about a century ago as the ‘‘seed and soil’’ analogy, where
tumors are supposed to have a ‘‘seminal influence’’ on the
metastatic micro-environment, and thereby act together
with the distant organ to effect tumor metastases [6]. The
identity of these seminal influences remains elusive. Both
genetic and epigenetic changes may play a role here.
Epigenetic alterations are of pivotal interest since they
cannot only influence tumor behavior but may also become
important therapeutic targets as these processes are po-
tentially reversible. Therapies that target DNA methylation
(DNA methyl-transferase (DNMT) inhibitors) or histone
modification (histone deacetylase (HDAC) inhibitors) al-
ready exist, but newer versions of these drugs need to be
developed to improve future clinical management [7].
Which mechanisms underlie development of distant
metastases remains a topic of debate. The two main but not
necessarily mutually exclusive hypotheses are the linear
and the parallel model of metastasis. According to the
linear model, genetic modifications progressively accu-
mulate in cancer cells of the primary tumor, whereby cells
with advantageous mutations will survive and expand
through clonal evolution [8]. If we translate this into epi-
genetic alterations such as promoter hypermethylation, one
would expect that tumor suppressor genes in metastases
show more methylation than primary carcinomas. An in-
crease in methylation values during local tumor progres-
sion has already been shown [9, 10]. In the parallel
progression model, cancer cells disseminate early during
tumor progression at a stage when the primary lesion is
small. Disseminated cells then evolve independently of the
primary tumor to form metastases. According to this latter
model, one would expect different methylation patterns in
primaries and their matched metastases.
Hypermethylation of tumor suppressor genes like APC,
RASSF1A, and FEZ1/LZTS1 in primary breast cancer has
been reported to correlate with development of distant
metastases [11, 12]. However, little is known about the
comparative methylation status of primary tumors and
matched distant metastases, possibly related to the fact that
metastatic material is rare. Rivenbark et al. compared the
methylation status of CST6 in primary breast cancers to
their lymph node metastases and showed that methylation-
dependent silencing occurred more frequently in the lymph
node metastases, possibly reflecting progression-related
epigenetic events according to the linear model for
metastasis [13].
Here we report promoter hypermethylation profiling for
40 tumor suppressor genes by methylation-specific multi-
plex ligation-dependent probe amplification (MS-MLPA)
in 53 primary breast carcinomas and their matched non-
bone distant metastases (skin, brain, lung or liver). This
study is part of a project where we study genotype and
phenotype of distant breast cancer metastases [14–16].
Extensive knowledge of the hypermethylation status of
tumor suppressor genes possibly involved in site-specific
metastasis could lead to novel biomarkers predicting site of
distant metastases and adjuvant targeted therapy strategies




This study was performed on 53 formalin-fixed paraffin
embedded (FFPE) samples of female primary breast car-
cinomas and 53 single corresponding metachronous non-
bone distant metastases. The samples were selected ran-
domly from an existing database entailing material from
300 patients from the departments of pathology of the
University Medical Center Utrecht, the Meander Medical
Center Amersfoort, the Deventer Hospital, the Rijnstate
Hospital Arnhem, Tergooi Hospitals, the Academic Med-
ical Center Amsterdam, the Radboud University Nijmegen
Medical Center, the Canisius Wilhelmina Hospital Ni-
jmegen, the Netherlands Cancer Institute Amsterdam, the
Medical Center Alkmaar, the Medical Center Zaandam, the
University Medical Center Groningen, the St. Antonius
Hospital Nieuwegein, the Diakonessenhuis Utrecht, the
Free University Medical Center Amsterdam, the Erasmus
Medical Center Rotterdam, the Gelre hospital Apeldoorn,
Isala clinics Zwolle, the Laboratory for Pathology En-
schede, the Laboratory for Pathology Dordrecht, and the
Laboratory for Pathology Foundation Sazinon Hoogeveen,
all in The Netherlands.
This study was performed in accordance with the insti-
tutional medical ethical guidelines. The use of anonymous
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or coded left over material for scientific purposes is part of
the standard treatment agreement with patients, and
therefore, informed consent was not required according to
Dutch law [17].
Molecular subtypes of breast tumors were assigned as
follows: Luminal A (ER?/PR?, HER2-, low cellular
proliferation), luminal B (ER?/PR?, HER2-, low cellular
proliferation or ER?/PR?, HER2?), triple negative or
basal type (ER-/PR-, HER2-), and HER2 enriched
(ER-/PR-, HER2?) as before [4].
To set methylation cut-off values, non-paired normal
breast tissue (n = 25) was used from breast reduction
specimens (mean age 39.4 years; n = 15) and autopsy
specimens (mean age 48.9 years; n = 10), with no sig-
nificant difference in age compared to breast cancer pa-
tients (p = 0.338). In addition, we analyzed normal non-
paired tissue from brain (n = 5), lung (n = 5), liver
(n = 5), and skin (n = 5) derived from our normal tissue
biobank to exclude that methylation values in distant
metastases would be influenced by admixture of normal
surrounding tissue, with again no significant difference in
age (45.8 years) compared to patients with breast cancer
(p = 0.111). The mean patient age at diagnosis was
52.8 years and 84 % of patients presented with invasive
ductal carcinoma. Follow-up ranged between sixteen and
315 months, and metastases were meanly diagnosed
55.4 months after the primary diagnosis. The localization
of the metastases that were included was brain (n = 11),
lung (n = 12), liver (n = 10), and skin (n = 20).
Clinicopathological characteristics are shown in Table 1.
DNA extraction
Four-micrometer sections were cut from each FFPE tissue
block and stained with haematoxylin and eosin (HE). The
HE-section was used to guide macro-dissection for DNA
extraction and to estimate tumor percentage. Only samples
containing 80 per cent tumor load or higher (both primary
tumor and metastasis) were selected. For proteinase
K-based DNA extraction, five 5-lm-thick slides were cut,
and tumor areas were macro-dissected using a scalpel.
Areas with necrosis, dense lymphocytic infiltrates, and pre-
invasive lesions were intentionally avoided. The DNA
concentration and absorbance at 260 and 280 nm were
measured with a spectrophotometer (Nanodrop ND-1000,
Thermo Scientific Wilmington, USA).
MS-MLPA
MS-MLPA was performed according to the manufacturer’s
protocol using the SALSA MS-MLPA probemixes ME001-
C2 Tumor suppressor-1 and ME003-A1 Tumor suppressor-
3 ‘‘Online Resource Tables 1 and 2,’’ each containing 15
internal control probes and in total 53 HhaI-sensitive
probes against the following tumor suppressor genes:
TP73, CASP8, VHL, RARB, MLH1 (2 loci), RASSF1A (2
loci), FHIT, APC, ESR1, CDKN2A/B, DAPK1, KLLN,
CD44, GSTP1, ATM, CADM1, CDKN1B, CHFR, BRCA1/
2, CDH13, HIC1, TIMP3 (2 loci), RDM2, RUNX3, HLTF
(2 loci), SCGB3A1 (2 loci), ID4 (2 loci), TWIST1, SFR4 (2
loci), DLC1 (2 loci), SFR5 (2 loci), BNI3, H2AFX (2 loci),
CCND2 (2 loci), CACNA1G, TGIF1, BCL2, and CAC-
NA1A. Since MS-MLPA is based on the methylation-sen-
sitive restriction enzyme HhaI, the choice of CpG site to be
evaluated within the promoter region is highly dependent
on the presence of the GCGC restriction site and not so
much based on correlation to expression in literature.
At least 50 ng of DNA was used in each MS-MLPA reac-
tion. DNA concentration control fragments, present in each
MS-MLPA mix, were evaluated to check for sufficient DNA
quantity. All reactions were performed according to the
manufacturer’s instructions in a Veriti 96Well ThermoCycler
(Applied Biosystems). A water sample, a 100 % methylated
(MCF-7 M.SssI methyl-transferase treated) control, and a
negative control (human sperm DNA) were taken along in
every MLPA run. Fragment separation was done by capillary
electrophoresis on an ABI-3730 capillary sequencer (Applied
Biosystems). Peak patterns derived by Genescan Analysis
were evaluated using Genemapper (version 4.1) and Coffal-
yser.net software (version 9.4, MRC-Holland, Amsterdam,
The Netherlands). The cumulative methylation index (CMI)
was calculated as the sum of all quantitative methylation val-
ues per tumor. Rawmethylation percentages of all genes were
depicted in ‘‘Online Resource Table 7.’’
Correlation between mRNA expression
and promoter methylation by TCGA
To correlate methylation of the investigated tumor sup-
pressor genes to mRNA expression, we used The Cancer
Genome Atlas (https://tcga-data.nci.nih.gov/tcga/).
TCGA Breast Invasive Carcinoma mRNA Expression
z-Scores (RNA Seq V2 RSEM) data (n = 1038) were
downloaded via The cBioPortal for Cancer Genomics [18,
19]. Illumina Infinium Human DNA Methylation 27 level 3
data (calculated beta values (M/M?U), gene symbols,
chromosomes, and genomic coordinates) were downloaded
via TCGA Data Portal (n = 313).
Statistical analyses were performed on data of all
available CpG sites of the TCGA database compared to the
CpG sites used for MS-MLPA.
Statistics
Unsupervised hierarchical clustering of log-transformed
quantitative methylation values was performed using non-
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Table 1 Clinicopathological characteristics of the metastatic breast cancer patients (n = 53) analyzed for methylation status of 40 tumor
suppressor genes with MS-MLPA
Feature Grouping N or value %
Age at diagnosis (in years) Mean 52.8 –
Range 27–88 –
Tumor size (in cm) B2 16 30
[2 and B5 26 49
[5 6 11
Not available 5 10
Histologic type Invasive ductal 45 84
Invasive lobular 4 8
Metaplastic 3 6
Micropapillary 1 2
Histologic grade (Bloom & Richardson) I 1 2
II 12 22
III 40 76




Lymph node status Positive 25 47
Negative 24 45
Not available 4 8




Molecular subtype Luminal A 11 21
Luminal B 28 53
Triple negative 12 22
HER2 enriched 2 4
Follow-up in months Mean 94 –
Range 16–315 –
Time between diagnosis of primary and metastasis (in months) Mean 55.4 –
Range 0.4–180.8 –
Time between diagnosis of metastasis and death (in months) Mean 26.6 –
Range 2.0–177.7 –
Treatment before resection of metastasis (adjuvant to
surgery of primary breast tumor)
Chemotherapy 19 36
Hormonal therapy 17 32
Radiotherapy 26 49
Combination of chemo-, hormonal
and/or radiotherapy
22 42
Not available 13 25
ER statusa
Primary ? 36 68
– 17 32
Metastasis ? 35 66
– 18 34
PR statusa
Primary ? 33 62
– 20 38
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parametric Spearman correlation with R software (version
3.0.1), including all cases that were tested with both MLPA
probemixes. Statistical analysis was executed on absolute
methylation percentages as well as on dichotomized val-
ues; the latter were determined by ROC curve analyses of
methylation values in normal breast tissue compared to
primary breast tumor tissue. The Kolmogorov–Smirnov
test and Shapiro–Wilk test were used to test for normality
of the distributions. Primary tumors and their paired
metastases were compared per gene using the Wilcoxon
signed-rank test. Non-paired analyses on patient differ-
ences and clinicopathological characteristics were com-
puted using the Mann–Whitney test. The dichotomized
values were analyzed using McNemars test or Chi square
test. Two-sided p values \0.05 were considered to be
statistically significant. Correction for multiple compar-
isons was performed by the Bonferroni–Holm approach.
Analysis of prognosis was performed using Kaplan–Meier
survival curves/log-rank test for univariate analyses and
Cox proportional hazard analysis for multivariate models
(entry and remove limits 0.05), calculating hazard ratios
(HR) with 95 % confidence intervals (CI). TCGA mRNA
z-scores were compared to percentages of DNA methyla-
tion by Pearson’s r correlation.
To evaluate whether site of distant metastasis is deter-
mined by specific methylation patterns of the primary tu-
mor or rather by inherent molecular subtype, we performed
logistic regression comparing the different metastatic sites
one by one with quantitative methylation status of indi-
vidual genes and molecular subtype as variables in the
model.
To evaluate whether adjuvant systemic treatment may
influence conversion from low methylation in the primary
to high methylation in the distant metastasis (or vice versa),
we grouped patients according to conversion per individual
gene and performed logistic regression for each individual
gene including adjuvant chemotherapy (yes or no) and
adjuvant hormonal therapy (yes or no) as variables in the
model.
All statistical calculations were done with IBM SPSS
Statistics 21.
Results
Normal versus tumor tissue
Appropriate cut-offs to dichotomize methylation values of
tumor suppressor genes, derived from ROC curve analysis
of MS-MLPA values in normal breast versus primary
breast tumor tissue, varied between 0.5 and 22.75 % for the
40 genes (53 loci) (Online Resource Table 8).
Although we only included samples of breast cancer
metastases that contained 80 percent tumor load or higher,
we wanted to further exclude that differences between
primaries and metastases were due to the admixture of
tumor micro-environment at distant sites. 17/40 genes
showed significantly higher methylation values in normal
lung, brain, or liver than in normal breast (Online Resource
Table 3; Fig. 1a shows CASP8 as an example). Also the
CMI values of normal liver and brain tissue were sig-
nificantly higher than the CMI of normal lung, skin, and
breast tissue (Fig. 1b).
Unsupervised hierarchical clustering of the quantitative
methylation values of primary breast tumors, paired distant
metastases, and normal tissues is shown in Fig. 2. Normal
liver and brain tissue seems to cluster together due to hy-
permethylation of some genes (APC, CDKN2B, CCND2
Table 1 continued
Feature Grouping N or value %
Metastasis ? 22 42
– 31 58
HER2-statusb








MAI mitotic activity index
a According to 10 % threshold for positivity
b According to DAKO-scoring system
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both loci, RASSF1A both loci and CASP8) as already
mentioned above, and normal breast, lung, and skin tissue
showed a related pattern.
Primary tumor versus metastasis
Using quantitative methylation values, 52.5 % (21/40) of
genes were significantly less methylated in the metastases
compared to their paired primary tumors : PRDM2
(p = 0.036), RARB-2 (p = 0.003), HLTF-2 (p = 0.013),
H2AFX-1 (p = 0.001), CACNA1G (p = 0.000), TGIF1
(p = 0.029), TIMP3-1 (p = 0.046), TP73 (p = 0.019),
FHIT (p = 0.002),APC (p = 0.048),CDKN2A (p = 0.002),
CDKN2B (p = 0.012), PTEN (p = 0.002), CD44
(p = 0.011),ATM (p = 0.000),CADM1 (p = 0.006),CHFR
(p = 0.005), BRCA2 (p = 0.001), HIC1 (p = 0.001), and
BRCA1 (p = 0.002). After correction for multiple compar-
isons, H2AFX-1, CACNA1G, ATM, BRCA2, and HIC1 re-
mained significant. CMI was not significantly different
between primaries and metastases (p = 0.454). Figure 3a
shows quantitative methylation values of CACNA1G in pri-
mary tumors and their distant metastases as an example.
Using dichotomized values, 55 % (22/40) of the tested tu-
mor suppressor genes, namely PRDM2 (p = 0.049), RARB-1
(p = 0.002), HLTF-2 (p = 0.031), TWIST1 (p = 0.012),
H2AFX both loci (p = 0.002 and p = 0.049), CACNA1G
(p = 0.013), TGIF1 (p = 0.002), TIMP3-3 (p = 0.013),
TP73 (p = 0.007),FHIT (p = 0.001),CDKN2A (p = 0.029),
DAPK1 (p = 0.004), PTEN (p = 0.008), CD44 (p = 0.000),
GSTP1 (p = 0.013),ATM (p = 0.000),CADM1 (p = 0.000),
CHFR (p = 0.031), BRCA2 (p = 0.013), HIC1 (p = 0.016),
andBRCA1 (p = 0.000), were significantly lessmethylated in
the metastases than in the primaries. After correction for
multiple comparisons, FHIT, CD44, ATM, CADM1, and
BRCA1 stayed significant.
PRDM2, HLTF-2, H2AFX-1, CACNA1G, TGIF1, TP73,
FHIT, CDKN2A, PTEN, CD44, ATM, CADM1, CHFR,
BRCA2, HIC1, and BRCA1 were significant in both quanti-
tative and dichotomized analyses. Of these, PRDM2,
H2AFX-1, TGIF1, TP73, CDKN2A, and CD44 were more
methylated in normal brain and/or liver tissues than in normal
breast, which indicates that the generally lower methylation
values in the distant metastases must be tumor cell specific
and excludes the potential admixture of cells from the distant
microenvironment being a confounder here.
When comparing primaries and metastases for all in-
vestigated tumor suppressor genes per individual patient,
significantly less methylation was seen in the metastases
compared to the primary tumor in 30.2 % (16/53; quanti-
tative) or 41.5 % (22/53; dichotomized) of patients (20.8
and 28.3 % after correction for multiple comparisons, re-
spectively). Only 15.1 % (8/53; quantitative) or 3.8 % (2/
53; dichotomized) of patients showed significantly more
methylation in the metastasis compared to the primary
tumor (3.8 or 1.9 %, respectively, if corrected for multiple
comparisons). These higher methylation values cannot be
explained by admixture of normal adjacent tissue in the
metastases, since none of these patients had a metastasis in
brain or liver, where high methylation values are found in
normal tissue.
In cluster analysis (Fig. 2), 32/53 pairs of primaries and
metastases clustered directly and another 9/53 pairs almost
directly (within three positions), indicating that methyla-
tion patterns of the tested tumor suppressor genes show
high patient specificity.
Molecular subtype
HER2 enriched tumors were excluded from statistical
analyses because of the small number. Triple negative
Fig. 1 Differences in quantitative methylation percentages of CASP8
a and the CMI b by MS-MLPA between various normal tissues.
N = 30 (brain n = 5, liver n = 5, lung n = 5, skin n = 5, and breast
n = 10). Small horizontal lines depict the median per group. The gray
horizontal line depicts the cut-off for hypermethylation of CASP8
(4.5 %). Chromosome location CASP8: chr2 (202122754-
202152434), CpG site MS-MLPA probe: 202122649, #bp from probe
to TSS: 104 and from probe to ATG: 104
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tumors tended to cluster together, but the difference be-
tween luminal A and B was less distinct (Fig. 4).
PRDM2, RARB, CACNA1G (Fig. 3b), SFRP4-2,
H2AFX, CACNA1A, TIMP3-1/2, and DLC1-1 showed
significantly less methylation in luminal A primary tumors
compared to luminal B and/or triple negative primary tu-
mors. Less methylation of SCGB3A1 was seen in triple-
negative tumors compared to the other subtypes. Further,
more methylation of ID4-2 was seen in luminal B tumors
compared to the other subtypes. When corrected for
metastatic site, these effects disappeared (Fig. 3c), indi-
cating that although subgroups were small, molecular
subtype is not a significant determinant of dissemination
site in this group (Online Resource Table 4). No differ-
ences were seen between the CMI of the different mole-
cular subtypes (p = 0.199) (Online Resource Table 5).
Concerning receptor status, 35 % (14/40; quantitative)
or 25 % (10/40; dichotomized) of the tumor suppressor
genes showed significantly higher methylation values in
ER-positive tumors compared to ER-negative tumors.
After correction for multiple comparisons, 5 % of the tu-
mor suppressor genes remained significant for both data
types: SCGB3A1 (both loci), ID4-1, SFRP5-2, H2AFX-1,
and FHIT.
In PR-positive tumors, this phenomenon was less dis-
tinct: 17.5 or 25 % of genes (quantitative or dichotomized
respectively) showed higher methylation values, but no
significance remained after multiple comparisons correc-
tion. Further, in HER2-positive tumors more methylation
was seen in 2.5 % (quantitative) or 7.5 % (dichotomized)
of tumor suppressor genes, but again no significance re-
mained when corrected for multiple comparisons.
Metastatic site
The following genes were significantly more methylated in
primary tumors metastasizing to brain, lung, or skin, than
to liver: PRDM2 (quantitative and dichotomized), RARB-1
(quantitative and dichotomized), HLTF-1 (quantitative),
ID4-2 (quantitative), TWIST1 (quantitative and di-
chotomized), SFRP4-2 (quantitative an dichotomized),
DLC1 (both loci; quantitative), H2AFX-2 (quantitative and
dichotomized), CACNA1G (quantitative and dichotomized)
(Fig. 3d), CACNA1A (quantitative), and TIMP3 (all three
loci; quantitative, -b; dichotomized). Also in the heatmap
(Fig. 4), a distinct cluster was formed by primary breast
tumors that metastasized to liver.
When corrected for molecular subtype by logistic re-
gression, the largest differences in methylation of indi-
vidual genes were seen between liver and skin (skin being
more methylated), and also the CMI was significantly
different here (p = 0.039). Figure 3e shows significantly
Fig. 2 Unsupervised hierarchical clustering analysis of log-trans-
formed quantitative methylation percentages of 40 tumor suppressor
genes (53 loci) in 53 primary breast tumors, 53 paired distant
metastases, and 30 normal tissues (breast n = 10, brain n = 5, lung
n = 5, liver n = 5, and skin n = 5). The sidebars depict location of
tissue and type (primary, metastasis, or normal tissue)
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more methylation of CACNA1G in brain, lung, and skin
compared to liver (quantitative data) as an example.
Association with clinicopathological characteristics
‘‘Online Resource Table 5’’ shows the association between
methylation in the primary tumor and classical clinico-
pathological characteristics. A higher CMI (quantitative
values) significantly correlated with higher MAI
(p = 0.040), although there was no association to lymph
node status, localization of metastases, and molecular
subtype. More aggressive tumor characteristics like higher
grade and MAI showed a tendency to higher methylation
values of individual genes.
Logistic regression for methylation conversion between
the primary cancers and their metastases did not show
significance for chemotherapy or hormonal therapy for any
of the genes, indicating that adjuvant systemic treatment is
Fig. 3 Quantitative methylation percentages of CACNA1G by MS-
MLPA in primary breast tumors and their corresponding distant
metastases (a). Methylation percentages in the primary tumor, divided
per molecular subtype (b) and corrected for dissemination localiza-
tion (brain) (c) are shown thereunder. At the bottom, methylation
percentages in the primary tumor, divided per dissemination location
(d) and corrected for molecular subtype (luminal B) (e), are
presented. Small horizontal lines depict the median per group. The
gray horizontal line depicts the cut-off for hypermethylation (8.5 %).
Chromosome location CACNA1G: chr17:48638429-48704832, CpG
site MS-MLPA probe: 48638728, #bp from probe to TSS: -300 and
from probe to ATG: 92
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not a confounder in methylation conversion. No significant
association was found (for both analysis methods) between
methylation of individual tumor suppressor genes and age
at diagnosis.
Prognostic value
Of the primary tumor characteristics, lymph node posi-
tivity, ER or PR negativity (10 % cut-off for positivity),
and HER2 positivity (DAKO score 3) were significantly
correlated to worse survival (Table 2). When comparing
survival curves of patients that showed methylation con-
version from low to high or vice versa with those that did
not, conversion of HLTF-2, ID4-2, SFRP4-1, and DAPK1
was correlated to worse overall survival (Fig. 5a). Con-
version for these genes was entered in Cox proportional
hazard analyses together, where SFRP4-1 (HR 2.3, 95 %
CI 1.03–5.05) and HLTF-2 (HR 2.2, 95 % CI 1.09–4.56)
remained significant (Table 3). When analyzing prognostic
value of methylation status of the individual genes in the
metastases for survival time from biopsy of metastases to
end of follow-up, three out of the four aforementioned
genes were again significant (ID4-2, SFRP4-1, and
DAPK1) (Fig. 5b).
Correlation of methylation to mRNA expression
by TCGA data extraction
Despite possible heterogeneity in methylation between in-
dividual CpG sites within the same promoter region, we
nevertheless tried to correlate methylation to mRNA ex-
pression by comparing the most closely located CpG sites
between TCGA data and our MS-MLPA loci (criteria for
matching:\1000 bp between CpG sites, significant inverse
correlation, Pearson’s r[-0.2; Online Resource Table 9).
Note that these results thus need to be interpreted with
caution.
The evaluated CpG sites/regions of ATM, BCL2, BRCA1,
BRCA2, CACNA1G, CADM1, CASP8, CCND2, CD44,
CDKN2B, CHFR1, DAPK1, ESR1, GSTP1, HLTF, ID4,
MLH1, PRDM2, PTEN, RARB, RASSF1, RUNX3, TIMP3,
TP73, and TWIST1 (15/40 genes) showed a significant in-
verse correlation with mRNA expression when quantitative
data were used ‘‘Online Resource Table 6.’’ Of these genes,
fourteen showed higher methylation values in primaries
compared to metastases in our cohort. For BNIP3, CAC-
NA1A, CDH13, CDKN1B, FHIT, HIC1, SCGB3A1, SFRP4,
SFRP5, and TGIF1 (10/40 genes), no correlation was found
between CpG site methylation and mRNA expression.
Fig. 4 Unsupervised hierarchical clustering analysis of log-trans-
formed quantitative methylation percentages of 40 tumor suppressor
genes (53 loci) in 53 primary breast tumors. The sidebars depict
dissemination location, subtype (luminal A, luminal B, triple
negative, and HER2 enriched), and ER status (according to 10 %
positivity)
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Table 2 Cox proportional hazards modeling of tumor suppressor gene methylation
Predictor Bivariate model p value N
Time between resection of
primary and end of follow-up
Time between resection of
metastasis and end of follow-up
Methylation status in metastasis





Conversion between primary and metastasis*





Luminal A – – 10
Luminal B 0.037 0.269 28
Triple negative 0.047 0.187 12
HER2 enriched 0.667 0.394 2
Location of metastasis
Brain – – 10
Lung 0.094 0.306 12
Liver 0.754 0.812 10
Skin 0.203 0.541 20
Tumor size
\2 cm – – 16
2–5 cm 0.699 0.039 25
[5 cm 0.756 0.330 6
Histologic type
Ductal – – 44
Lobular 0.553 0.940 4
Metaplastic 0.774 0.823 3
Micropapillary 0.506 0.344 1
Histologic grade
I – – 1
II 0.963 0.663 11
III 0.026 0.303 40
MAI 0.359 0.712 53
Lymph node status 0.045 0.884 48
ER status 0.000 0.260 53
PR status 0.001 0.372 53
HER2 status 0.041 0.613 53
Age at diagnosis primary 0.385 0.202 53
Chemotherapy 0.118 0.998 24
Radiotherapy 0.064 0.024 37
Hormone therapy 0.236 0.907 22
Combination therapy
Chemoradiation – – 7
Radiohormonal therapy 0.097 0.822 3
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Discussion
DNA methylation has a similar potential as genetic alter-
ations in serving as a selectable driver during clonal ex-
pansion or metastatic dissemination and could therefore
yield valuable markers for cancer detection and prognosis
as well as targets for new therapeutic strategies [20]. Our
study design allowed comparison of primary breast tumors
to their paired distant metastases at different locations,
enabling intra- and inter-individual comparison.
Our results show a general tendency for lower methy-
lation at primary tumor-methylated regions in the matched
metastases of 21/40 tumor suppressor genes. It is unlikely
that admixture of cells from the tumor micro-environment
at distant sites have caused these lower methylation values.
First, we only included metastatic samples that contained at
least 80 % tumor. Second, methylation values in normal
breast were lower than in normal tissues from skin, lung,
brain, and liver, so admixture of such normal cells (espe-
cially from liver and brain) would have raised methylation
values. Third, all normal tissues clustered together in un-
supervised analysis, which also showed that primary tu-
mors and their paired metastases cluster together.
Therefore, most of these hypermethylation events are likely
patient specific and subject to specific selection across
metastatic dissemination and expansion, emphasizing the
need for personalized cancer treatment.
Higher CMI correlated with higher MAI as did methy-
lation values of individual genes, indicating that prolif-
eration rate correlates with methylation, which is
biologically plausible. Adjuvant chemotherapy or hor-
monal therapy did not seem to influence methylation
conversion.
To our knowledge, our study is the first that compared
promoter methylation in a large group of multiple local-
izations of distant human breast cancer metastases to their
matched primary breast carcinomas and we tried to apply
the ‘‘reporting recommendations for tumor markers’’
(REMARK criteria) as adequately as possible [21]. Several
studies have been performed addressing methylation dif-
ferences between primary tumors and metastases. Howev-
er, their methods failed to draw conclusions on intra-
patient differences and site-specific markers. Limitations
included: description of a single metastatic site or tumor
suppressor gene, non-matched pairs of primaries and
metastases, methylation only in the primary tumor (com-
pared to the metastasizing tendency), or the use of mouse
models instead of patient material [11, 12, 22–26].
Rivenbark et al. demonstrated ‘‘epigenetic progression’’ by
showing more methylation in lymph node metastases
compared to the primary breast tumor [13], but Wu et al.
showed no differences in methylation of seven tumor
suppressor genes in primary breast carcinomas compared to
their matched distant metastases [27]. The discrepant
findings with our generally lower methylation values in
distant metastases (largely in line with results in head and
neck squamous cell carcinomas [28]) are likely related to
differences in distant metastasis localizations, differences
in study populations and sample sizes, pairing of normal
tissue, the inclusion of paired metastases, and variation in
tumor suppressor genes and CpG regions studied, Further,
methodologies for demonstration of methylation status
(QM-MSP, methylation-specific PCR analysis, bisulfite
sequencing, differential methylation hybridization, etc.)
Table 2 continued
Predictor Bivariate model p value N
Time between resection of
primary and end of follow-up
Time between resection of
metastasis and end of follow-up
Chemohormonal therapy 0.114 0.992 4
Chemoradiation ? hormonal therapy 0.931 0.174 4
CMI primaries 0.642 0.876 53
CMI metastases 0.726 0.630 53
Clinicopathological characteristics are compared to time between resection of primary or metastasis and end of follow-up
* Variables which are put in the multivariate model
Table 3 Multivariate model of conversion between primary and
metastasis in time between resection of metastasis and end of follow-
up
Parameter Significance Hazard ratio 95 % CI
Lower limit Upper limit
SFRP4-1 0.042 2.279 1.028 5.052
HLTF-2 0.029 2.223 1.085 4.556
Bivariate analysis identified several significant (p\ 0.05) predictors
of survival. Reference categories were set for those predictors with
more than two categories. Based upon number of patients included, 4
predictors could be tested in multivariate Cox proportional hazard
models. HLTF-2, ID4-2, SFRP4-1, and DAPK1 were used to generate
composite models through forward conditional testing, with p\ 0.05
as the basis for retaining and removing variables
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differ between studies. In our institute, we have extensive
experience using MS-MLPA [10, 29–31], a restriction en-
zyme-based assay that allows a multi-target approach on
small amounts of DNA extracted from formalin-fixed
paraffin embedded material. This technique shows a very
good correlation with other techniques such as bisulfite py-
rosequencing and (QM) MSP [32–37]. Besides, a tumor or
metastasis-initiating clone or sub-clone in each individual has
a unique DNA methylation signature that is closely main-
tained across metastatic dissemination [20]. However, for
each tumor, we chose one of many available tissue blocks
(that contained the largest amount of tumor load), which
could have led to sampling bias. A previous study from our
group clearly demonstrated that, although most variation in
methylation status is present between individual breast can-
cers, clonal epigenetic heterogeneity is seen within most
primary breast carcinomas, indicating that methylation re-
sults from a single random sample may not be representative
of the whole tumor [30]. In addition, for 12 genes, two dif-
ferent CpG loci were analyzed separately, and exact results
showeddifferences inmethylation frequencies, indicating the
presence of heterogeneous methylation. However, unsuper-
vised hierarchical clustering showed an almost perfect cor-
relation between six and eight of the 12 genes of which
different CpG sites were analyzed. These limitations could
explain perhaps some but clearly not all of the differences in
methylation values between primary and metastasis.
To correct for the differences between locations of dis-
semination, differences betweenmolecular subtypes should be
taken into account, since they are known to preferentially
metastasize to specific distant sites [4, 38]. For instance, a
general hypomethylation of basal-like tumors compared to
differentialmethylation acrossnon-basal-like subtypes is often
reported [38, 39]. We indeed saw some clustering of triple
negative tumors and one cluster almost entirely composed of
ER-positive cancers, but no evident hypomethylationwas seen
compared to other subtypes. Distinct methylation patterns
relative to breast cancer subtype and normal breast tissue as
shown by Bardowell et al. [38] were also not seen. Further,
some of the chosen genes were significantly more methylated
in tumors that metastasized to specific localizations (even
when corrected for molecular subtype), which could lead to
novel biomarkers predicting site of distant metastases and
adjuvant targeted therapy strategies that could prevent such
metastases from becoming clinically manifest.
In a therapeutic setting, the correlation between
methylation and mRNA/protein expression may become
relevant, which is why we explored TCGA data. Generally,
methylation at the investigated CpG sites by MS-MLPA,
seemed inversely correlated to mRNA expression levels as
demonstrated before [40] (despite possible heterogeneity in
methylation between individual CpG sites used for MS-
MLPA and TCGA test), indicating their relevance in gene
silencing. Future studies should take into account actual
protein expression of tumor suppressor genes in metastases
in relation to methylation status.
Theoretically, less methylation in metastases would
prognostically be beneficial for the patient because of
Fig. 5 Kaplan–Meier survival curves of time between resection of
metastasis to end of follow-up of HLTF-2, ID4-2, SFRP4-1 and
DAPK1 of conversion of methylation status in the primary tumors
compared to paired metastases (a). The dashed line depicts conver-
sion from negative in the primary tumor to positive in the metastasis
and the gray line depicts conversion from positive in the primary
tumor to negative in the metastasis. Survival curves of ID4-2, SFRP4-
1, and DAPK1 of methylation status of metastases are shown in (b).
Chromosome location HLTF-2: chr3:148747904–148804341, CpG
site MS-MLPA probe: 148804223, #bp from probe to TSS: -105 and
from probe to ATG: -105. Chromosome location ID4-2:
chr6:19837601–19842431, CpG site MS-MLPA probe: 19837620,
#bp from probe to TSS: -20 and from probe to ATG: 365.
Chromosome location SFRP4-1: chr7:37945535–37956525, CpG site
MS-MLPA probe: 37956166, #bp from probe to TSS: -10632 and
from probe to ATG: -9086. Chromosome location DAPK1:
chr9:90113885–90323549, CpG site MS-MLPA probe: 90113281,
#bp from probe to TSS: 603 and from probe to ATG: 711
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reactivation of these tumor suppressor genes. However,
survival analysis showed that conversion of HLTF-2, ID4-
2, SFRP4-1, and DAPK1 from positive in the primary
tumor to negative in the metastasis was correlated to
worse overall survival. Interestingly, methylation status of
3/4 of these genes (ID4-2, SFRP4-1 and DAPK1) pre-
dicted worse survival when hypermethylated in metas-
tases. Most important independent predictors for shorter
survival time over lymph node positivity and ER status
were SFRP4 and HLTF, which are known predictors of
worse survival. Hypermethylation of HLTF seems to
predict poor outcome in colorectal [41, 42] and lung
cancer [43]. SFRP4 is been shown to be an independent
predictor of shorter survival in myelodysplastic syndrome
[44] and invasive bladder cancer [45]. However, these
studies emphasize hypermethylation status in primary tu-
mors, and no studies were found on hypermethylation of
these markers in paired metastases in relation to survival.
Promoter hypermethylation of tumor suppressor genes is
known to be an early event during carcinogenesis [9, 10].
There are several possible explanations for the trend that
less promoter methylation of the investigated genes is
seen in the metastases. First, the spread of tumor cells
may take place even prior to methylation. It has been
demonstrated before that in breast, prostate, and esopha-
geal cancer, bone marrow disseminated tumor cells
(DTCs: any tumor cell that has left the primary lesion and
traveled to an ectopic environment, not necessarily
forming a metastasis) display significantly fewer genetic
aberrations than primary tumor cells [46–49]. Dis-
semination of tumor cells that are still evolving may lead
to allopatric selection and expansion of variant cells
adapted to specific microenvironments [50]. Second, it
could be that methylation is a dynamic process and may
even vary in different stages of the cell cycle. Graff et al.
have shown that E-cadherin (a gene involved in homo-
typic cell–cell adhesion) in cell lines is hypermethylated
when put in a culture model system for basement mem-
brane invasion and hypomethylated in a tumor growth
model [51]. The reversibility of methylation of tumor
suppressor genes could therefore be beneficial to tumor
spread, whether it is a random process or a response to
specific signals.
In summary, we have shown that hypermethylation of
tumor suppressor genes detected by MS-MLPA is gener-
ally lower in the distant metastases compared to the pri-
mary tumors. We already knew that hypermethylation, in
contrast to DNA mutations, is reversible, but whether this
is a random or controlled principle has not been fully
elucidated. The question rises if the difference in methy-
lation pattern between these primaries and metastases
could be explained by the loss/rearrangement of hyper-
methylation. Since we have shown that the 21/40 tested
tumor suppressor genes show less methylation in metas-
tases with respect to their matched primary carcinomas,
methylation is probably not an epigenetic factor that could
be used for therapy against metastatic tumor spread.
However, since different metastasizing localizations show
different methylation patterns, screening for a specific
pattern that predicts most likely site of metastases could be
a useful clinical tool. Further, methylation status of several
genes seems to predict survival after metastases. Therefore,
more tumor suppressor genes should be screened on larger
databases and heterogeneity should be ruled out to include
all tumor subclones.
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